Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-02-21Clinical Trial Update: QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine [Phase 2]
ImmunityBio's Phase 2 trial of the NANT Neoadjuvant TNBC Vaccine for triple-negative breast cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-02-21Clinical Trial Update: QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy [Phase 1, Phase 2]
The QUILT-3.049 trial of the NANT TNBC vaccine in triple-negative breast cancer has been withdrawn, ending a Phase 1/2 combination immunothe…
-
CLINICAL_TRIALS research · 2025-02-20Clinical Trial Update: Tracking Triple-negative Breast Cancer Evolution Through Therapy [NA]
This clinical trial update tracks how triple-negative breast cancer evolves during therapy, with the study currently active but not recruiti…
-
CLINICAL_TRIALS research · 2025-02-20Clinical Trial Update: Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy [Phase 2]
A Phase 2 neoadjuvant trial in invasive triple-negative breast cancer evaluating stereotactic radiotherapy with a PD-1 monoclonal antibody a…
-
CLINICAL_TRIALS trial_result · 2025-02-19Clinical Trial Update: Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer [Phase 2]
Phase 2 trial comparing single-agent carboplatin to carboplatin plus everolimus in advanced triple-negative breast cancer has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-02-17Clinical Trial Update: The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy
A clinical trial update on how the intestinal microbiome may influence response to immunotherapy in triple-negative breast cancer; the study…
-
CLINICAL_TRIALS research · 2025-02-14Clinical Trial Update: Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation
Enrollment status update for a trial of intensive adjuvant therapy in triple-negative breast cancer patients with BRCA mutations (enrolling …
-
CLINICAL_TRIALS research · 2025-02-13Clinical Trial Update: A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple-Negative and HER2+ Breast Cancer Patients [NA]
A Phase II single-arm study is exploring the efficacy and safety of adding hyperbaric oxygen as neoadjuvant therapy for patients with triple…
-
CLINICAL_TRIALS research · 2025-02-12Clinical Trial Update: Efficacy of Interleukin-2 in Triple Negative Breast Cancer [Phase 1, Phase 2]
This entry notes a planned Phase 1/2 clinical trial evaluating interleukin-2 for triple-negative breast cancer, with recruitment not yet sta…
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer [Phase 1]
Seagen's SEA-TGT (SGN-TGT) Phase 1 safety study in advanced cancers has been terminated. The study enrolled patients across multiple cancer …
-
CLINICAL_TRIALS research · 2025-02-06Clinical Trial Update: QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC [Phase 2]
A Phase 2 trial is evaluating QL1706 in combination with chemotherapy, with or without bevacizumab, as first-line therapy for relapsed/metas…
-
CLINICAL_TRIALS research · 2025-01-30Clinical Trial Update: Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC [Phase 2]
A Phase 2 clinical trial in metastatic PD-L1 positive triple-negative breast cancer evaluating induction therapy with paclitaxel plus bevaci…
-
CLINICAL_TRIALS trial_result · 2025-01-29Clinical Trial Update: Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating trilaciclib in combination with sacituzumab govitecan-hziy for triple-negative breast cancer was terminated; resu…
-
CLINICAL_TRIALS research · 2025-01-29Clinical Trial Update: Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer
A clinical trial update describes evaluating Sacituzumab Govitecan in Chinese patients with metastatic triple-negative breast cancer, focusi…
-
CLINICAL_TRIALS withdrawal · 2025-01-29Clinical Trial Update: Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating a dendritic cell-based treatment combined with immunotherapy for metastatic or unresectable triple-negative breast …
-
CLINICAL_TRIALS research · 2025-01-28Clinical Trial Update: Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients [Phase 3]
A Phase 3 non-inferiority trial evaluating an MRNA-lncRNA model for low-risk triple-negative breast cancer, currently not yet recruiting.
-
CLINICAL_TRIALS research · 2025-01-27Clinical Trial Update: BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC [Phase 2]
Phase 2 clinical trial update for IvoneScimab in combination with a Trop2-targeted antibody-drug conjugate for brain metastases in patients …
-
CLINICAL_TRIALS research · 2025-01-23Clinical Trial Update: Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer [Phase 2]
Phase 2 trial evaluating camrelizumab in combination with TCb versus TCb alone as neoadjuvant therapy for triple-negative breast cancer. Rec…
-
CLINICAL_TRIALS research · 2025-01-20Clinical Trial Update: Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients [NA]
This clinical trial update describes a home-based exercise program being studied during neoadjuvant therapy for early breast cancer patients…
-
CLINICAL_TRIALS research · 2025-01-20Clinical Trial Update: MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBC [NA]
This clinical trial compares MRI screening to symptom-directed surveillance for brain metastases in patients with triple-negative or HER2-po…
-
CLINICAL_TRIALS trial_result · 2025-01-17Clinical Trial Update: COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. [Phase 1]
Phase 1 clinical trial update for COM701, a PVRIG inhibitor, in adults with advanced solid tumors; the study has completed.
-
CLINICAL_TRIALS trial_result · 2025-01-16Clinical Trial Update: Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP) [Phase 2]
A Phase 2 neoadjuvant trial evaluating toripalimab in combination with docetaxel and carboplatin for localized triple-negative breast cancer…
-
CLINICAL_TRIALS trial_result · 2025-01-15Clinical Trial Update: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) [Phase 1, Phase 2]
This document is a completed Phase 1/Phase 2 clinical trial update for CAB-ROR2-ADC evaluating safety and efficacy in non-small cell lung ca…
-
CLINICAL_TRIALS research · 2025-01-13Clinical Trial Update: Phase II Clinical Trial of PD-L1 in Combination with Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy with or Without Radiotherapy for Advanced Triple-negative Breast Cancer. [Phase 2]
Phase II clinical trial evaluating a PD-L1 inhibitor in combination with metronomic vinorelbine, cyclophosphamide, and capecitabine, with or…
-
CLINICAL_TRIALS research · 2025-01-10Clinical Trial Update: A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer [Phase 2]
This document reports a Phase 2 clinical study of 9MW2821 in combination with a PD-1 inhibitor for locally advanced or metastatic triple-neg…